NICE - Endorsed Technology Appraisals 2007/2008

The following NICE Technology Appraisals were endorsed by the DoH in 2007/2008

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA102 - Parent-training / education programmes in the management of children with conduct disorders - HSC (SQSD) (NICE) 12/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C - HSC (SQSD) (NICE) 27/07

​National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA110 - Follicular Lymphoma - Rituximab

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA112 - Breast Cancer (Early) - Hormonal Treatments - HSC (SQSD) (NICE) 28/07

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA113 - Inhaled Insulin for the Treatment of Diabetes Mellitus Types 1&2

  • In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete.  Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA114 - Drug Misuse - Methadone and Buprenorphine - HSC (SQSD) (NICE) 14/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA115 - Drug Misuse - Naltrexone - HSC (SQSD) (NICE) 15/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA116 - Breast Cancer - Gemcitabine - HSC (SQSD) (NICE) 29/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA117 - Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis - HSC (SQSD) (NICE) 31/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA118 - Colorectal Caner - Bevacizumab & Cetuximab - HSC (SQSD) (NICE) 16/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA119 - Fludarabine monotherapy for the first-line treatment of Chronic Lymphocytic Leukaemia (CLL) - HSC (SQSD) (NICE) 30/07 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA120 - Heart Failure - Cardiac Resynchronisation - HSC (SQSD) (NICE) 08/08 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA121 - Carmustine implants and temolozomide for glioma - HSC (SQSD) (NICE) 09/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA122 - Alteplase for the treatment of Acute Ischaemic Stroke

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA125 - Adalimumab for the treatment of psoriatic arthritis

​National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA127 - Multiple Sclerosis - Natalizumab - HSC (SQSD) (NICE) 04/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA128 - Stapled haemorroidopexy for the treatment of haemorrhoids - HSC (SQSD) (NICE) 14/08 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA129 - Multiple myeloma - bortezomib monotherapy - HSC (SQSD) (NICE) 10/08 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA132 - Ezetimibe for the treatment of hypercholesterolaemia

National Institute for National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA133 - Omalizumab for severe persistent allergic asthma

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA135 - Pemetrexed disodium for the treatment of malignant pleural mesothelioma - HSC (SQSD) (NICE) 11/08 

Back to top